In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Bill Smith (Senior Fellow and Director, Life Sciences Initiative at The Pioneer Institute) to discuss how the 340B program has evolved from a safety net drug discount program into a major source of hospital revenue, what new research suggests about charity care and Medicaid access, and why transparency, hospital consolidation, and broader drug pricing policy are reshaping incentives across oncology and biopharma.

Key Topics:
340B Origins: Medicaid best price, safety net intent, clinic and hospital eligibility.
Hospital Arbitrage: Buy-low sell-high incentives, affluent satellite sites, oncology drug spreads.
Charity Care: Lower reported charity care, Medicaid access concerns, variation across hospital systems.
Transparency Reforms: State reporting laws, separate audited accounts, minimum charity care requirements.
Policy Collisions: Inflation Reduction Act (IRA) price controls, Most-Favored-Nation (MFN) pressure, oncology consolidation, biopharma investment risks.

Opinions expressed are those of the speakers. Recorded 6/5/26. The Vital Health Podcast is a production of Vital Transformation LLC © 2026.

In this episode of the Vital Health Podcast, host <a href="https://www.linkedin.com/in/duane-schulthess-66ba39b7/">Duane Schulthess</a> speaks with <a href="https://www.linkedin.com/in/william-smith-phd-54628b18/">Bill&nbsp;Smith</a> (Senior Fellow and Director, Life Sciences Initiative at <a href="https://www.linkedin.com/company/pioneer-institute-for-public-policy-research/">The Pioneer Institute</a>) to discuss how the 340B program has evolved from a safety net drug discount program into a major source of hospital revenue, what new research suggests about charity care and Medicaid access, and why transparency, hospital consolidation, and broader drug pricing policy are reshaping incentives across oncology and biopharma.
Key Topics:
<ul data-start="982" data-end="1512">
<li data-start="982" data-end="1074" data-section-id="1peq6hi">340B Origins: Medicaid best price, safety net intent, clinic and hospital eligibility.</li>
<li data-start="1075" data-end="1179" data-section-id="crugk7">Hospital Arbitrage: Buy-low sell-high incentives, affluent satellite sites, oncology drug spreads.</li>
<li data-start="1180" data-end="1289" data-section-id="1md5czd">Charity Care: Lower reported charity care, Medicaid access concerns, variation across hospital systems.</li>
<li data-start="1290" data-end="1401" data-section-id="1mugpb2">Transparency Reforms: State reporting laws, separate audited accounts, minimum charity care requirements.</li>
<li data-start="1402" data-end="1512" data-section-id="1e21uam">Policy Collisions: Inflation Reduction Act (IRA) price controls, Most-Favored-Nation (MFN) pressure, oncology consolidation, biopharma investment risks.</li>
</ul>
Opinions expressed are those of the speakers. Recorded 6/5/26. The Vital Health Podcast is a production of Vital Transformation LLC &copy; 2026.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess, Managing Director of Vital Tran…